





Curriculum Vitae

Ofir Goldberger

 Lab phone (650) 498.7759
 E-mail ofir . goldberger [at] stanford . edu

Research experience

2007-present	Postdoc in the lab of Prof. Mark M. Davis, Stanford School Of Medicine, Dept. of Immunology and Microbiology Research interests: 1. A system's biology experimental approach towards construction of immunological networks though high throughput assays. 2. Understanding T cells' sensitivities to cytokine stimulation.
--------------	--

Education

2002-2007	Weizmann Institute of Science, Rehovot, Israel, Faculty of Life Sciences, Department of Immunology Thesis advisor: Professor Lea Eisenbach Thesis title: <i>Adoptive Cell Transfer For Cancer Immunotherapy – Pitfalls And Resolutions</i> Thesis topics: 1) Basic mechanisms of tumor escape and the interaction of tumor and the immune system 2) Factors affecting the infiltration of cytotoxic T cells into tumors
1999-2002	Weizmann Institute of Science, Rehovot, Israel, Faculty of Life Sciences, Department of Immunology M.Sc., March 2002 Thesis advisor: Professor Lea Eisenbach Thesis topic: <i>Active and Passive Anti-cancer Immune Strategies</i>
1996-1999	Tel Aviv University, Tel Aviv, Israel, Faculty of life sciences. B.Sc. degree, February 1999



Military service

1993-1996	Israel Defense Force, mandatory service, command position. Rank upon discharge: Staff sergeant Current rank: Sergeant First Class
-----------	---

Work experience

1997-1999	Dun & Bradstreet international (Israel), Programmer, Assistant to IT project manager
1992-1993	Dun & Bradstreet international (Israel), Computer data input and parsing

Computer skills

	Microsoft Office tools Programming languages: MatLab, Perl, OO Perl, Clipper Operating systems: DOS, Windows, Mac, Linux Databases: MySQL, dBase III
--	---

Languages

	Hebrew & English – fluent
--	---------------------------



Abstracts, lectures and posters

1. 2004 FISEB (Federation of Israeli Societies for Experimental Biology) – **Abstract and poster.**
2. 2005 Keystone conference on "Basic Aspects of Tumor Immunology II" – **Lecture: Cell Precursor Frequency Alone is Insufficient to Trigger Tumor Regression.** Awarded travel scholarship.

Publications

1. Shen-Orr SS, Goldberger O, Garten Y, Rosenberg-Hasson Y, Lovelace PA, Hirschberg DL, Altman RB, Davis MM, Butte AJ. **Towards a cytokine-cell interaction knowledgebase of the adaptive immune system.** Pac Symp Biocomput. 2009: Accepted.
2. *Goldberger O*, Volovitz I, Machlenkin A, Tzeheval E, Vadai E, Eisenbach L. **Exuberated numbers of tumor-specific T cells result in antigen silencing variant formation.** Cancer Res. 2008 May 1;68(9):3450-7.
3. Volovitz I, Mor F, Machlenkin A, *Goldberger O*, Marmor Y, Eisenbach L, Cohen IR. T-cell seeding: **Neonatal transfer of anti-myelin basic protein T-cell lines renders Fischer rats susceptible later in life to the active induction of EAE.** Submitted.
4. Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, *Goldberger O*, Reiter Y, Tzeheval E, Benhar I, Eisenbach L. **Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.** Cancer Immunol Immunother. 2006 Jun 1; 2007 Feb;56(2):217-26.



5. Machlenkin A, Paz A, Bar Haim E, *Goldberger O*, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. **Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.** *Cancer Res.* 2005 Jul 15;65(14):6435-42.
6. Machlenkin A, *Goldberger O*, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L. **Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.** *Clin Cancer Res.* 2005 Jul 1;11(13):4955-61.
7. Lee SH, Bar-Haim E, *Goldberger O*, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L. **Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.** *Immunol Lett.* 2004 Feb 15;91(2-3):119-26.
8. Lee SH, Bar-Haim E, Machlenkin A, *Goldberger O*, Volovitz I, Vadai E, Tzehoval E, Eisenbach L. **In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.** *Cancer Gene Ther.* 2004 Mar;11(3):237-48.
9. GeneCards (www.genecards.org), an integrated database of human genes – Contributor.